중재적 종양학 시장 : 제품 유형별, 시술 유형별, 암 유형별, 최종 사용자별 시장 예측(2026-2032년)

The Interventional Oncology Market is projected to grow by USD 4.58 billion at a CAGR of 7.65% by 2032.

Interventional Oncology Executive Summary

Interventional oncology is now a core pillar of multidisciplinary cancer care, using image-guided cancer therapy to diagnose, ablate, embolize, and palliate solid tumors with minimally invasive precision. The field is most established in liver cancer, metastatic colorectal cancer to the liver, lung lesions, renal tumors, bone metastases, and selected pancreatic and soft-tissue indications, where tumor ablation, transarterial chemoembolization (TACE), transarterial radioembolization (TARE/Y-90), and targeted biopsy can complement surgery, systemic therapy, and radiation.

Demand is structurally supported by the global cancer burden. The International Agency for Research on Cancer estimated about 20 million new cancer cases and 9.7 million cancer deaths in 2022, with new cases projected to reach roughly 35 million by 2050. For health systems and cancer centers, this creates a clear mandate: expand access to minimally invasive cancer treatment, build integrated interventional radiology capacity, and align clinical pathways with evidence-based oncology guidelines.

Transformative Shifts in the Interventional Oncology Landscape

The interventional oncology landscape is shifting from procedure-based service lines toward integrated, disease-specific cancer programs. Hospitals are increasingly embedding interventional radiologists in tumor boards, liver cancer clinics, lung nodule programs, and metastatic disease pathways so that patients are evaluated earlier for ablation, embolization, and locoregional therapy rather than only after multiple treatment failures.

Technology is also reshaping clinical delivery. Cone-beam CT, fusion imaging, navigation software, robotic assistance, and advanced embolic platforms are improving procedural planning and targeting. At the same time, oncology is moving toward combination strategies, including locoregional therapy paired with immunotherapy or targeted agents, particularly in hepatocellular carcinoma, where major clinical guidelines recognize TACE, ablation, and radioembolization as important options for selected patients.

Cumulative Impact of Artificial Intelligence in Interventional Oncology

Artificial intelligence is becoming a cumulative force across the interventional oncology workflow. In screening and diagnosis, AI-enabled imaging tools can help detect lesions, characterize tumor boundaries, and prioritize cases for specialist review. During planning, segmentation and radiomics can support volumetric assessment, ablation margin estimation, and patient selection for image-guided cancer therapy.

The operational value is equally important. AI can support scheduling, inventory planning, radiation dose management, and outcomes tracking across interventional oncology programs. As adoption matures, the highest-impact use cases will likely combine validated algorithms with structured clinical data, multidisciplinary review, and real-world evidence registries that measure local control, survival, complications, length of stay, and patient-reported outcomes.

Key Regional Insights: Global Interventional Oncology Demand

Asia-Pacific is positioned for rapid interventional oncology expansion because it carries a high burden of liver, lung, gastric, and colorectal cancers, while major markets such as China, Japan, South Korea, India, and Australia continue investing in advanced imaging and cancer infrastructure. North America remains a global innovation hub, supported by large academic cancer centers, established reimbursement pathways for many image-guided procedures, and strong adoption of tumor ablation, TACE, and Y-90 radioembolization.

Europe benefits from mature oncology networks and guideline-driven care, with Germany, France, Italy, Spain, and the United Kingdom driving procedure standardization and clinical research. Latin America, led by Brazil and Mexico, is expanding access to minimally invasive cancer treatment but still faces uneven distribution of specialist centers. The Middle East is investing in tertiary hospitals and oncology modernization, particularly in GCC countries, while Africa remains an access-constrained region where workforce training, imaging availability, cancer screening, and referral pathway development are central to long-term improvement.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gaining relevance as cancer incidence rises and governments expand tertiary hospital capacity, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines at different stages of interventional oncology adoption. The GCC is accelerating demand through national cancer strategies, advanced hospital construction, oncology center development, and medical tourism, especially in Saudi Arabia, the United Arab Emirates, and Qatar.

The European Union supports interventional oncology through cross-border research collaboration, regulatory harmonization, cancer-plan funding priorities, and guideline-based care, although reimbursement remains country-specific. BRICS countries are important high-need markets because Brazil, Russia, India, China, and South Africa combine large populations with growing oncology infrastructure requirements. G7 countries remain central to clinical evidence generation, advanced imaging adoption, and premium technology uptake, while NATO members overlap with many high-income health systems that prioritize resilient medical infrastructure, imaging capacity, and advanced cancer care readiness.

Key Country Insights: Priority Markets for Interventional Oncology

The United States leads in academic interventional oncology, clinical trials, Y-90 radioembolization adoption, tumor ablation, and multidisciplinary cancer care, while Canada shows strong adoption in urban cancer centers but faces geographic access challenges across remote and rural areas. Mexico and Brazil are expanding minimally invasive oncology services through major public and private hospitals, although affordability, reimbursement variability, and regional disparities remain barriers. In Europe, the United Kingdom, Germany, France, Italy, and Spain have established interventional radiology networks and guideline-driven oncology systems, while Russia has significant oncology demand and uneven access across regions.

China is scaling interventional oncology rapidly through hospital expansion, high liver cancer demand, and growing advanced imaging capacity; India is growing through private oncology networks, public cancer initiatives, medical tourism, and rising interventional radiology capability. Japan and South Korea are advanced markets with strong expertise in hepatocellular carcinoma management, ablation, and image-guided interventions. Australia combines high-quality cancer care with centralized specialist services, making referral optimization, telehealth-enabled care coordination, and rural access important priorities.

Actionable Recommendations for Interventional Oncology Leaders

Industry leaders should build interventional oncology programs around disease-specific pathways, not isolated procedures. The strongest near-term opportunities are in hepatocellular carcinoma, colorectal liver metastases, lung tumors, renal tumors, and bone metastasis palliation, where image-guided therapy can reduce recovery time and support multidisciplinary treatment sequencing.

Hospitals should invest in interventional radiology workforce development, advanced imaging, ablation platforms, embolization capabilities, radiation safety, and outcomes registries. Device and technology providers should prioritize evidence generation, physician training, patient selection tools, and workflow integration. Payers and policymakers should assess value using procedure safety, length of stay, repeat treatment rates, quality of life, and total cost of care rather than device cost alone.

Research Methodology

This executive summary is based on a structured review of public health data, cancer epidemiology, clinical practice guidelines, peer-reviewed literature, regulatory information, and observable adoption patterns in interventional oncology. Core references include internationally recognized sources such as the International Agency for Research on Cancer, World Health Organization materials, national cancer agencies, and professional society guidance in oncology and interventional radiology.

The analysis emphasizes verified, data-backed indicators rather than speculative claims. Market interpretation was developed by triangulating cancer burden, procedure relevance, healthcare infrastructure, technology adoption, reimbursement maturity, regional access conditions, and the role of multidisciplinary cancer care across leading and emerging markets.

Conclusion: Interventional Oncology as a Strategic Growth Platform

Interventional oncology is moving from a specialized procedural niche to a strategic cancer-care capability. The convergence of rising cancer incidence, advanced imaging, minimally invasive therapy, AI-enabled planning, and multidisciplinary decision-making is expanding its role across diagnosis, local tumor control, palliation, and combination treatment pathways.

Organizations that invest now in clinical integration, evidence-based protocols, patient access, and measurable outcomes will be best positioned to lead. In a cancer landscape defined by complexity and capacity pressure, interventional oncology offers a scalable, precision-focused approach to improving care delivery and patient experience.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Interventional Oncology Market, by Product Type

• 7.1. Ablation Devices
• 7.2. Embolization Devices
• 7.3. Support & Access Devices

8. Interventional Oncology Market, by Procedure Type

• 8.1. Tumor Ablation Procedures
• 8.2. Vascular Interventions
• 8.3. Tumor Biopsy Procedures
• 8.4. Palliative Procedures

9. Interventional Oncology Market, by Cancer Type

• 9.1. Liver Cancer
• 9.2. Lung Cancer
• 9.3. Kidney (Renal) Cancer
• 9.4. Breast Cancer

10. Interventional Oncology Market, by End-Use

• 10.1. Hospitals
• 10.2. Specialty Clinics

11. Interventional Oncology Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Interventional Oncology Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Interventional Oncology Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Accuray Incorporated
• 15.2. Baxter International Inc.
• 15.3. Bayer AG
• 15.4. Becton, Dickinson and Company
• 15.5. Boston Scientific Corporation
• 15.6. Cook Medical Inc.
• 15.7. GE HealthCare Technologies Inc.
• 15.8. Johnson & Johnson Services, Inc.
• 15.9. Koninklijke Philips N.V.
• 15.10. Medtronic plc
• 15.11. Merit Medical Systems, Inc.
• 15.12. Profound Medical Corp.
• 15.13. Siemens Healthineers AG
• 15.14. Sirtex Medical Limited
• 15.15. Teleflex Incorporated
• 15.16. Terumo Corporation
• 15.17. Varian Medical Systems, Inc.